Trial Profile
Comparative effectiveness and safety between reduced dose dabigatran, reduced dose rivaroxaban and warfarin in elderly Atrial Fibrillation Patients over 85 years
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2018
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism and thrombosis; Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- 04 Jul 2018 Results (n=4722) published in the Journal of the American Geriatrics Society.
- 28 Nov 2017 New trial record
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association